Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | NK cells | 0.37161 | 0.00e+00 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | NK cells | 0.453808 | 0.00e+00 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | NK cells | -0.262758 | 5.87e-15 |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | NK cells | 0.251979 | 1.00e-42 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | NK cells | 0.688356 | 0.00e+00 |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | Advanced stages of melanoma | Immunotherapy | pembrolizumab | post | CD8+ T cells | -0.452686 | 0.00e+00 |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | Advanced stages of melanoma | Immunotherapy | pembrolizumab | pre | CD8+ T cells | -0.539761 | 0.00e+00 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | pre | NK cells | -0.515728 | 1.46e-39 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | pre | CD8+ T cells | -0.362631 | 1.92e-29 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | NK cells | 0.328771 | 8.72e-03 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | NK cells | 0.463251 | 4.95e-03 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | CD8+ T cells | 0.349514 | 1.82e-38 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | NK cells | -0.55832 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | NK cells | -1.1715 | 4.19e-10 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | post | NK cells | 0.731263 | 2.22e-36 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | NK cells | -0.296176 | 1.07e-11 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | CD8+ T cells | -0.261312 | 1.49e-21 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | 0.538068 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
SPON2 | metacluster_168.12 | PRDM4; ZKSCAN3; ZNF200; ZNF319; ZNF808 (directAnnotation). PRDM4; ZNF319 (inferredBy_Orthology). |
SPON2 | transfac_pro__M01357 | PBX1 (directAnnotation). |
SPON2 | metacluster_137.1 | NFE2L1; NFE2L1; ZNF177 (directAnnotation). |
SPON2 | hocomoco__FOXP1_HUMAN.H11MO.0.A | FOXP1 (directAnnotation). |
SPON2 | transfac_pro__M07434 | TRPS1 (directAnnotation). |
SPON2 | transfac_pro__M01267 | FOSL1 (directAnnotation). |
SPON2 | transfac_pro__M07304 | PBX1; PBX2; PBX3; PKNOX1 (directAnnotation). |
SPON2 | cisbp__M00262 | ARX (directAnnotation). |
SPON2 | metacluster_74.14 | HNF1B (directAnnotation). |
SPON2 | metacluster_174.4 | PBX1; PBX1; PBX1; PBX1 (directAnnotation). |
SPON2 | metacluster_184.8 | DUXA (directAnnotation). |
SPON2 | tfdimers__MD00563 | DBP; MAF (directAnnotation). |
SPON2 | tfdimers__MD00138 | IRF1; IRF2; IRF3; IRF4; IRF5; IRF7; IRF8; IRF9; MYB (directAnnotation). |
SPON2 | taipale_tf_pairs__TEAD4_HOXA13_RCATWCCNNNNNNTTTAYNNN_CAP_repr | HOXA13; TEAD4 (directAnnotation). |
SPON2 | taipale_tf_pairs__POU2F1_EOMES_NTATKCAGYGTNA_CAP | EOMES; POU2F1 (directAnnotation). |
SPON2 | tfdimers__MD00370 | YY1; ZNF384 (directAnnotation). |
SPON2 | metacluster_119.1 | ZNF677 (directAnnotation). |
SPON2 | metacluster_2.4 | ZIM3; ZIM3; ZIM3; ZIM3 (directAnnotation). |
SPON2 | tfdimers__MD00561 | CRX (directAnnotation). |
SPON2 | transfac_pro__M04918 | EGR1 (directAnnotation). |
SPON2 | metacluster_32.32 | PRDM6 (directAnnotation). |
SPON2 | transfac_pro__M08187 | ABL1 (directAnnotation). |
SPON2 | hocomoco__SOX9_HUMAN.H11MO.1.B | SOX9 (directAnnotation). |
SPON2 | taipale_tf_pairs__SOX17_ACCGAACAAT_HT | SOX17 (directAnnotation). |
SPON2 | tfdimers__MD00472 | EP300; HOXA13 (directAnnotation). |
SPON2 | transfac_pro__M06075 | ZNF197 (directAnnotation). |
SPON2 | transfac_pro__M06000 | ZNF233 (directAnnotation). |
SPON2 | metacluster_4.4 | NANOG; NANOG; SOX2; SOX2; SOX2; SOX3; SOX4; SOX4 (directAnnotation). NANOGP8; SOX2 (inferredBy_Orthology). |
SPON2 | cisbp__M00839 | FOXP1 (directAnnotation). |
SPON2 | tfdimers__MD00369 | ZNF384 (directAnnotation). |
SPON2 | transfac_pro__M04927 | FOXA1 (directAnnotation). |
SPON2 | tfdimers__MD00386 | GTF2IRD1; POU5F1 (directAnnotation). |
SPON2 | tfdimers__MD00299 | ETS1; SRY (directAnnotation). |
SPON2 | taipale_cyt_meth__POU2F2_NTAATNTATGCN_eDBD_repr | POU2F2 (directAnnotation). |
SPON2 | cisbp__M00838 | FOXP1 (directAnnotation). |
SPON2 | swissregulon__hs__HDX | HDX (directAnnotation). |
SPON2 | transfac_pro__M05617 | ZNF500 (directAnnotation). |
SPON2 | cisbp__M05891 | SOX10 (directAnnotation). |
SPON2 | tfdimers__MD00240 | E2F1; TCF7L1 (directAnnotation). |
SPON2 | metacluster_12.1 | ZNF3 (directAnnotation). |
SPON2 | tfdimers__MD00269 | CRX; PBX1 (directAnnotation). |
SPON2 | taipale_tf_pairs__GCM1_ELK3_ACCCGCANCCGGAAGN_CAP_repr | ELK3; GCM1 (directAnnotation). |
SPON2 | tfdimers__MD00488 | ELF1; HDX (directAnnotation). |
SPON2 | metacluster_22.15 | BACH1 (directAnnotation). |
SPON2 | tfdimers__MD00470 | TP53 (directAnnotation). |
SPON2 | metacluster_22.39 | NFE2L2 (directAnnotation). |
SPON2 | kznf__ZSCAN29_TF_Evolution_PBM | ZSCAN29 (directAnnotation). |
SPON2 | transfac_pro__M06081 | ZNF99 (directAnnotation). |
SPON2 | metacluster_22.14 | BACH1 (inferredBy_Orthology). |
SPON2 | tfdimers__MD00454 | ARID3A; PAX4 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |